Compare Fox Corp Class B (FOX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Sana Biotechnology Inc — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Fox Corp Class B is far larger — about 30.3× Sana Biotechnology Inc's market cap, and Fox Corp Class B pays a 1.02% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Sana Biotechnology Inc for 23 Days on average.
| FOX | SANA | |
|---|---|---|
Market Cap | $25.36B | $836.71M |
Volume | 886,620 | 4,507,444 |
Sector | Media | Health |
52-Week High | $67.76 | $5.92 |
52-Week Low | $44.39 | $2.68 |
Typical Hold Time | 75 Days | 23 Days |
Enterprise Value | $28.72B | $749.96M |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX stock trades at $55.89, down 0.16% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 surpassing the $1.44 estimate. Revenue grew to $16.30 billion in 2025, and net income margin improved to 13.88%. Analysts maintain a consensus price target of $84.75, implying significant upside, with 42% recommending Buy.
The outlook is positive given earnings momentum and reasonable valuation multiples, but risks include projected net cash flow turning negative in 2026 and competitive pressures in media. Investor sentiment is supported by bullish analyst targets, though attention is needed on debt levels and future profitability trends.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
